Halozyme Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Halozyme Therapeutics, Inc.
The ex-chief medical officer at Novartis is now CEO at the UK-based biotech, which he he told Scrip could have a ‘transformational’ therapy to protect patients after a heart attack.
Aurobindo’s acquisition of 15 brands from Pfizer and Viatris to gain entry to Indonesia marks a role reversal of sorts as Pfizer has been licensing generics from Aurobindo. Scrip takes a look at some of the opportunities and challenges in this growing Southeast Asian market.
The Swiss major’s partner Halozyme has revealed that the US launch for the subcutaneous version of the checkpoint inhibitor Tecentriq will be put back until 2024 following questions from the Food and Drug Administration about manufacturing processes.
The following four neurological products are likely to reach market next year. Carving out sales will be an entirely different problem.
- Drug Delivery
- Drug Discovery Tools
- Other Names / Subsidiaries
- Antares Pharma, Inc.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.